Publications by authors named "Jan Schellens"

Claim this Profile
B
Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial.
Mark T J VAN Bussel, Nathalie Bravenboer, Huib VAN Essen, Petur Snaebjornsson, Natasha M Appelman-Dijkstra, Jan Hm Schellens

Anticancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors.
Daphne W M Voogd, Merel J J Lucassen, Ruud van der Noll, Sybrand W J Zielhuis, David Boss, Jan H M Schellens

Oncol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.
Jonathan E Knikman, Mirjam de With, Niels Heersche, Marta Lopez-Yurda, Arnold Baars, Jan H M Schellens

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe fluoropyrimidine toxicity in older adults with cancer with DPYD wild type.
Edwin Brokaar, Jonathan Knikman, Loes Visser, Frederiek van den Bos, Linda Henricks, Jan Schellens

Fundam Clin Pharmacol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro studies on stability and phosphatase activity of the anticancer agent LB-100 and its active hydrolysis product endothall.
Hans Rollema, Robert Volkmann, Panayiotis Zagouras, Fred Nelson, Tamim Braish, Jan H M Schellens

Int J Pharm· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.
Alaa Embaby, Sanne C F A Huijberts, Liqin Wang, Rodrigo Leite de Oliveira, Hilde Rosing, Jan H M Schellens

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD.
Jonathan E Knikman, Qinglian Zhai, Carin A T C Lunenburg, Linda M Henricks, Stefan Böhringer, Jan H M Schellens

Genome Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.
Gwénaël Le Teuff, Nathalie Cozic, Jean-Christophe Boyer, Valérie Boige, Robert B Diasio, Jan H M Schellens

Br J Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens.
Jonathan E Knikman, Marta Lopez-Yurda, Didier Meulendijks, Maarten J Deenen, Jan H M Schellens

Clin Pharmacol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival of Patients With Cancer With Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis.
Jonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, Linda M Henricks, Carin A T C Lunenburg, Jan H M Schellens

J Clin Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Anas Gazzah, Ulrik Lassen, Jan H M Schellens

Nat Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters".
Mirjam de With, Jonathan Knikman, Jan H M Schellens, Hans Gelderblom, Annemieke Cats

Clin Pharmacol Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Jan H M Schellens

J Immunother Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide.
Keith T Schmidt, Fatima Karzai, Marijo Bilusic, Lisa M Cordes, Cindy H Chau, Jan H M Schellens

Oncologist· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.
Mirjam de With, Jonathan Knikman, Femke M de Man, Carin A T C Lunenburg, Linda M Henricks, Jan H M Schellens

Clin Pharmacol Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.
Hui K Gan, Michael Millward, Mathilde Jalving, Ignacio Garrido-Laguna, Jason D Lickliter, Jan H M Schellens

Oncologist· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
Jill J J Geenen, Gwen M H E Dackus, Philip C Schouten, Dick Pluim, Serena Marchetti, Jan H M Schellens

Int J Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.
Charlotte W Duinkerken, Vincent A de Weger, Wouter A Dreschler, Lisette van der Molen, Dick Pluim, Jan H M Schellens

Otol Neurotol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
Emilie M J van Brummelen, Sanne Huijberts, Carla van Herpen, Ingrid Desar, Frans Opdam, Jan Schellens

Oncologist· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer.
Rosemarie de Haan, Michel M van den Heuvel, Judi van Diessen, Heike M U Peulen, Erik van Werkhoven, Jan H M Schellens

Clin Cancer Res· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.
Mark T J van Bussel, Ahmad Awada, Maja J A de Jonge, Morten Mau-Sørensen, Dorte Nielsen, Jan H M Schellens

Br J Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Jean-Pierre Delord, Antoine Italiano, Ahmad Awada, Philippe Aftimos, Nadine Houédé, Jan H M Schellens

Target Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
Céleste Lebbé, Antoine Italiano, Nadine Houédé, Ahmad Awada, Philippe Aftimos, Jan H M Schellens

Target Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Vivek Subbiah, Ulrik Lassen, Elena Élez, Antoine Italiano, Giuseppe Curigliano, Jan H M Schellens

Lancet Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No relation between docetaxel administration route and high-grade diarrhea incidence.
Jeroen J M A Hendrikx, Frederik E Stuurman, Ji-Ying Song, Vincent A de Weger, Jurjen S Lagas, Jan H M Schellens

Pharmacol Res Perspect· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis